4-(4-Fluorophenyl)-2-(3-methylthiophenyl)-5-(pyridin-4-yl)-1H-imidazole | 162580-94-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(4-Fluorophenyl)-2-(3-methylthiophenyl)-5-(pyridin-4-yl)-1H-imidazole
• 英文别名: 4-(4-Fluorophenyl)-2-(3-methylthiophenyl)-5-(4-pyridyl)-1H-imidazole；4-[4-(4-fluorophenyl)-2-(3-methylsulfanylphenyl)-1H-imidazol-5-yl]pyridine
• CAS: 162580-94-1
• 化学式: C₂₁H₁₆FN₃S
• 分子量: 361.443
• InChiKey: OJHOIAOSQSNDFE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  66.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(4-Fluorophenyl)-2-(3-methylthiophenyl)-5-(pyridin-4-yl)-1H-imidazole 生成 4-(4-Fluorophenyl)-2-(3-methylsulfinylphenyl)-5-(pyridin-4-yl)-1H-imidazole
  参考文献：
  名称：

  Pyridyl imidazoles

  摘要：

  新型2,4,5-三芳基咪唑化合物及其在治疗中的应用组合。

  公开号：

  US05656644A1
• 作为产物：
  描述：

  4-吡啶甲醇 在 咪唑 、 copper diacetate 、 ammonium acetate 、 溶剂黄146 、 lithium diisopropyl amide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 23.92h， 生成 4-(4-Fluorophenyl)-2-(3-methylthiophenyl)-5-(pyridin-4-yl)-1H-imidazole
  参考文献：
  名称：

  Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase

  摘要：

  Members of three classes of pyridinylimidazoles bind with varying affinities to CSBP (p38) kinase which is a member of a stress-induced signal transduction pathway. Based upon SAR and protein homology modeling, the pharmacophore and three potential modes of binding to the enzyme are presented. For a subset of pyridinylimidazoles, binding is shown to correlate with inhibition of CSBP kinase activity, whereas no significant inhibition of PKA, PKC alpha and ERK kinase activity is observed. Copyright (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0968-0896(96)00212-x

文献信息

• Pyrimidinyl imidazoles
  申请人：SmithKline Beecham Corporation

  公开号：US05916891A1

  公开（公告）日：1999-06-29

  Novel 2,4,5-triaryl imidazole compounds and compositions for use in therapy.

  新型2,4,5-三芳基咪唑化合物和用于治疗的组合物。
• [EN] TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES<br/>[FR] IMIDAZOLES A TRI-SUBSTITUTION ET PROPRIETES THERAPEUTIQUES MULTIPLES
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：WO1995002591A1

  公开（公告）日：1995-01-26

  (EN) This invention relates to a novel group of imidazole compounds, processes for the preparation thereof, the use thereof in treating cytokine mediated diseases, and pharmaceutical compositions for use in such therapy.(FR) L'invention concerne un nouveau groupe de composés d'imidazoles, leurs procédés de préparation, leur utilisation dans le traitement de maladies induites par la cytokine ainsi que des compositions pharmaceutiques destinées à être utilisées dans ladite thérapie.

  这项发明涉及一种新型的咪唑化合物群，其制备过程，用于治疗细胞因子介导疾病的用途以及用于此类治疗的药物组合物。
• [EN] IMIDAZOLES FOR TREATING CYTOKINE MEDIATED DISEASE<br/>[FR] IMIDAZOLES ACTIVES CONTRE LES MALADIES TRANSMISES PAR LA CYTOKINE
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：WO1995003297A1

  公开（公告）日：1995-02-02

  (EN) Novel 2,4,5-triaryl imidazole compounds and compositions for use in therapy, such as cytokine mediated diseases.(FR) Ces nouveaux composés et compositions à base de 2,4,5-triaryle-imidazole sont destinés aux thérapies de traitement des maladies du type de celles qui sont transmises par la cytokine.

  (中文) 这些新的2,4,5-三芳基咪唑化合物和组合物用于治疗细胞因子介导的疾病，如细胞因子介导的疾病。
• Novel compounds
  申请人：SmithKline Beecham Corporation

  公开号：US20030064997A1

  公开（公告）日：2003-04-03

  Novel 2,4,5-triaryl imidazole compounds and compositions for use in therapy.

  小说2,4,5-三芳基咪唑化合物及其在治疗中的应用组成物。
• Combination therapy for treating, preventing or managing proliferative disorders and cancers
  申请人：——

  公开号：US20040067953A1

  公开（公告）日：2004-04-08

  The present invention relates to methods and compositions designed for the treatment, management or prevention of cancer. The methods of the invention comprise the administration of an effective amount of one or more inhibitors of JNK in combination with the administration of an effective amount of one or more other agents useful for cancer therapy. The invention also provides pharmaceutical compositions comprising one or more inhibitors of JNK in combination with one or more other agents useful for cancer therapy. In particular, the invention is directed to methods of treatment and prevention of cancer by the administration of an effective amount of one or more inhibitors of JNK in combination with standard and experimental chemotherapies, hormonal therapies, bone marrow transplants, stem cell replacement therapies, biological therapies/immunotherapies and/or radiation therapies for treatment or prevention of cancer. Also included are methods of treatment of cancer by the administration of one or more inhibitors of JNK in combination with surgery, alone or in further combination with standard and experimental chemotherapies, hormonal therapies, bone marrow transplants, stem cell replacement therapies, biological therapies/immunotherapies and/or radiation therapies.

  本发明涉及用于治疗、控制或预防癌症的方法和组合物。本发明的方法包括施用有效量的一种或多种 JNK 抑制剂，并结合施用有效量的一种或多种其他用于癌症治疗的制剂。本发明还提供了药物组合物，其中包含一种或多种 JNK 抑制剂与一种或多种其他有助于癌症治疗的药物。特别是，本发明涉及通过施用有效量的一种或多种JNK抑制剂与标准和实验性化疗、激素疗法、骨髓移植、干细胞替代疗法、生物疗法/免疫疗法和/或放射疗法联合治疗或预防癌症的方法。还包括通过施用一种或多种JNK抑制剂结合手术、单独或进一步结合标准和实验性化疗、激素疗法、骨髓移植、干细胞替代疗法、生物疗法/免疫疗法和/或放射疗法治疗癌症的方法。